lunes, 6 de enero de 2020

A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects | BMC Pharmacology and Toxicology | Full Text

A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects | BMC Pharmacology and Toxicology | Full Text

FKB327 is a biosimilar of the adalimumab reference product (RP). The primary objective was to assess the relative bioavailability of FKB327 after a single subcutaneous (SC) dose via prefilled syringe (PFS), au...
Authors:Jim Bush, Kazuki Kawakami and Rafael Muniz
Citation:BMC Pharmacology and Toxicology 2019 20:87
Content type:Research article
Published on: 

No hay comentarios: